Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
0(0%)
Results Posted
50%(3 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_3
1
10%
Ph not_applicable
1
10%
Ph phase_4
2
20%
Ph phase_1
6
60%

Phase Distribution

6

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
6(60.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
2(20.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(6)
Terminated(2)
Other(2)

Detailed Status

Completed6
Terminated2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (60.0%)
Phase 31 (10.0%)
Phase 42 (20.0%)
N/A1 (10.0%)

Trials by Status

completed660%
terminated220%
unknown220%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_1

Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)

NCT06795204
completedphase_4

A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT05400369
completedphase_1

Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval

NCT04821063
unknownphase_1

Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

NCT05660720
unknownphase_1

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

NCT04898907
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06795204Phase 1

Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)

Completed
NCT05400369Phase 4

A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Completed
NCT04821063Phase 1

Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval

Completed
NCT05660720Phase 1

Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

Unknown
NCT04898907Phase 1

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

Unknown
NCT00324324Phase 3

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

Terminated
NCT01910415Phase 1

Phase 1, QT/QTC Interval Study in Healthy Subjects

Completed
NCT00062231Not Applicable

Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer

Terminated
NCT00758199Phase 4

Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery

Completed
NCT00824070Phase 1

Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10